What Is P21 Peptide?

P21, also written P021 or Peptide 021, is a small synthetic peptide compound developed from ciliary neurotrophic factor (CNTF), a naturally occurring protein that supports the development and maintenance of the nervous system. Researchers designed P21 to capture the activity of one short region of CNTF in a molecule that is far smaller and more stable than the full protein. Since its first description in 2010, it has been studied in cell cultures and a range of rodent models, mainly in neuroscience research on neurogenesis, synaptic plasticity and tau biology.

This article covers where P21 comes from, how its structure was engineered, what mechanism studies have reported, and why it is often confused with an unrelated protein that shares its name.

Where P21 comes from: CNTF and the problem with large proteins

CNTF belongs to the interleukin-6 (IL-6) family of cytokines. It acts on many cell types and has long interested neuroscientists because of its role in neuronal survival and development. As a research tool, though, the full protein is difficult to work with: it is large, unstable and, like other neurotrophic factors, has properties that limit how it can be studied.

To get around these problems, the laboratory of Prof. Khalid Iqbal at the New York State Institute for Basic Research in Developmental Disabilities set out to find the smallest part of CNTF that still carried its activity. Using epitope mapping, the group traced that activity to one short region of the protein and derived a tetrapeptide from it. The work built on an earlier, larger compound from the same group, an 11-mer CNTF peptide called Peptide 6 (P6). P21 is a trimmed-down, chemically modified successor to P6.

Structure of P21

P21 is written as Ac-DGGLAG-NH2. Each part of that notation reflects a design choice.

• DGGL is the core four-amino-acid sequence: aspartic acid, glycine, glycine and leucine. It corresponds to the biologically active region of human CNTF at amino acid residues 148–151.
• Ac- means the N-terminus is acetylated, and -NH2 means the C-terminus is amidated. Capping both ends this way is a common technique for making short peptides more resistant to breakdown.
• AG is an adamantylated glycine added at the C-terminus, included to increase lipophilicity and reduce breakdown by exopeptidases.

Adamantane is a bulky, cage-shaped hydrocarbon. Attaching it to a peptide makes the molecule more fat-soluble and physically harder for enzymes to cleave from the end.

The published molecular weight of P21 is 578.3.

What mechanism studies have reported

Most of what is known about how P21 works comes from the Iqbal group and its collaborators. The research points to two linked pathways.

Competitive inhibition of LIF signaling. Leukemia inhibitory factor (LIF) is another IL-6-family cytokine that inhibits the formation of neural progenitor cells from stem cells. In published studies, P21 competitively inhibited LIF activity, measured as reduced phosphorylation of the signaling protein STAT3, as its parent 11-mer peptide does. Because LIF suppresses neurogenesis in the dentate gyrus of the hippocampus, partial inhibition of LIF is the proposed route by which P21 affects the formation of new neurons in research models.

Increased BDNF expression. Brain-derived neurotrophic factor (BDNF) is a key signaling protein in neuronal growth and plasticity. Researchers reported that P21 increases BDNF expression by increasing its transcription. In one model, they linked downstream changes to a BDNF-mediated reduction in glycogen synthase kinase-3β (GSK-3β) activity, observed in animal studies and confirmed in primary cultured cortical neurons. GSK-3β is one of the main enzymes that phosphorylates tau, which is why this pathway interests tau researchers.

Research models in which P21 has been studied

P21 has been used across several distinct animal and cell models. Everything below describes preclinical laboratory findings.

Normal adult mice. The first report, published in 2010, described P21 in normal adult C57Bl6 mice. The researchers reported increased neurogenesis and maturation of newly born neurons in the granular cell layer and subgranular zone of the dentate gyrus.

Triple-transgenic (3xTg-AD) mice. The 3xTg-AD mouse carries mutations that produce both amyloid-beta and tau pathology and is widely used in Alzheimer's disease research. In this model, researchers measured tau phosphorylation, neurogenesis and synaptic markers, and reported lower phosphorylated tau levels in P21-exposed animals than in controls, with a smaller change in amyloid-beta measures. Later work from the same group examined whether the timing of exposure relative to the onset of pathology affected these measures.

Ts65Dn mice. The Ts65Dn mouse is a model used in Down syndrome research. In this model, researchers reported lower GSK-3β activity and higher levels of synaptic plasticity markers, including BDNF and phosphorylated CREB, in P21-exposed animals compared with controls.

CDKL5 deficiency models. A 2024 study examined P21 in cell and mouse models of CDKL5 deficiency disorder, a genetic neurodevelopmental condition. The researchers noted that the absence of Cdkl5 negatively affects neuronal proliferation, survival and maturation in these models.

P21 peptide vs. the p21 protein

A large share of searches for "p21" are about something else entirely, so it's worth separating the two.

p21, usually written in lowercase and also known as p21^Cip1/Waf1 or by its gene name CDKN1A, is a naturally occurring protein of about 21 kilodaltons. It is a cyclin-dependent kinase inhibitor and one of the best-known targets of the tumor suppressor p53. It is central to cell-cycle arrest, DNA-damage response and cellular senescence research. The "21" in its name refers to its molecular mass.

P21 (P021) is a synthetic tetrapeptide compound derived from CNTF. It has a molecular weight of about 578, not 21,000, and no structural or functional relationship to the p21 protein. The "21" is simply part of a compound numbering series from the laboratory that developed it, which also includes P6.

When searching the literature, the terms "P021," "Peptide 021" or "CNTF-derived peptide" return far more relevant results for the synthetic compound than "p21," which is dominated by cell-cycle research.

Current research status and limitations

It is important to be clear about what the evidence does and does not show.

• The peer-reviewed literature on P21 consists of cell-culture and animal studies. It is not approved by any regulatory agency for any use.
• Much of the published work comes from one research group and its collaborators, so independent replication is limited.
• Some properties attributed to P21's design, such as blood–brain barrier permeability, have been inferred mainly from indirect measures in the same group's studies.
• Findings in rodent models do not necessarily translate to other species or systems.

For researchers, these limitations shape experimental design. Appropriate controls, independent verification and careful documentation of compound identity matter as much here as with any early-stage research compound.

Sourcing P21 for laboratory research

For studies using P21, compound identity should be confirmed from the supplier's certificate of analysis before use. Storage and handling should follow the compound's data sheet and the laboratory's own standards.

Power Peptides supplies P21 for laboratory research use only.

Frequently asked questions

Is P21 the same as the p21 protein?

No. P21 (P021) is a synthetic tetrapeptide derived from CNTF. The p21 protein (CDKN1A) is a natural cyclin-dependent kinase inhibitor involved in cell-cycle control. The two are unrelated.

What is P21 derived from?

It is derived from residues 148–151 of human ciliary neurotrophic factor (CNTF), with an adamantylated glycine added at the C-terminus.

Who developed P21?

It was developed in the laboratory of Prof. Khalid Iqbal at the New York State Institute for Basic Research in Developmental Disabilities.

What does the research on P21 focus on?

Published work focuses on neurogenesis, synaptic plasticity, LIF and BDNF signaling, and tau phosphorylation in cell and rodent models.

References

1. Li B, Wanka L, Blanchard J, Liu F, Chohan MO, Iqbal K, Grundke-Iqbal I. Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice. FEBS Letters. 2010;584(15):3359–3365. doi:10.1016/j.febslet.2010.06.025
2. Chohan MO, Li B, Blanchard J, Tung YC, Heaney AT, Rabe A, Iqbal K, Grundke-Iqbal I. Enhancement of dentate gyrus neurogenesis, dendritic and synaptic plasticity and memory by a neurotrophic peptide. Neurobiology of Aging. 2011;32(8):1420–1434. doi:10.1016/j.neurobiolaging.2009.08.008
3. Kazim SF, Blanchard J, Dai CL, Tung YC, LaFerla FM, Iqbal IG, Iqbal K. Neurobiology of Disease. 2014;71:110–130. doi:10.1016/j.nbd.2014.07.001 (study of P21 in 3xTg-AD mice; PMID 25046994)
4. Baazaoui N, Iqbal K. Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound. Alzheimer's Research & Therapy. 2017;9(1):45. doi:10.1186/s13195-017-0273-7
5. Kazim SF, Blanchard J, Bianchi R, Iqbal K. Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome. Scientific Reports. 2017;7:45561. doi:10.1038/srep45561
6. Mottolese N, Loi M, Trazzi S, Tassinari M, Uguagliati B, Candini G, Iqbal K, Medici G, Ciani E. Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder. Journal of Neurodevelopmental Disorders. 2024;16(1):65. doi:10.1186/s11689-024-09583-4

This article summarizes published scientific literature. Products offered by Power Peptides are for in-vitro laboratory research use only and are not for human or animal use. The statements in this article have not been evaluated by the FDA. Products offered by Power Peptides are not intended to diagnose, treat, cure or prevent any disease.